FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385074337> ?p ?o ?g. }

• W4385074337 endingPage "1074" @default.
• W4385074337 startingPage "1072" @default.
• W4385074337 abstract "Adjuvant therapy with immune checkpoint inhibitors (ICIs) became standard for resected stage III/IV melanoma after the results from the CheckMate-238 and KEYNOTE-054 studies. However, 30% to 40% of patients relapse despite adjuvant therapy. 1 Weber J. Mandala M. Del Vecchio M. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017; 377: 1824-1835https://doi.org/10.1056/NEJMoa1709030 Crossref PubMed Scopus (1494) Google Scholar ,2 Eggermont A.M.M. Blank C.U. Mandala M. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018; 378: 1789-1801https://doi.org/10.1056/NEJMoa1802357 Crossref PubMed Scopus (1171) Google Scholar" @default.
• W4385074337 created "2023-07-23" @default.
• W4385074337 creator A5001548963 @default.
• W4385074337 creator A5004823373 @default.
• W4385074337 creator A5006114282 @default.
• W4385074337 creator A5006485099 @default.
• W4385074337 creator A5008492560 @default.
• W4385074337 creator A5015806707 @default.
• W4385074337 creator A5017218622 @default.
• W4385074337 creator A5019107852 @default.
• W4385074337 creator A5019984620 @default.
• W4385074337 creator A5022167252 @default.
• W4385074337 creator A5023198820 @default.
• W4385074337 creator A5027395430 @default.
• W4385074337 creator A5027968676 @default.
• W4385074337 creator A5031480514 @default.
• W4385074337 creator A5035779817 @default.
• W4385074337 creator A5055605020 @default.
• W4385074337 creator A5056320023 @default.
• W4385074337 creator A5072852205 @default.
• W4385074337 creator A5082278497 @default.
• W4385074337 creator A5083397493 @default.
• W4385074337 creator A5083713436 @default.
• W4385074337 creator A5087984672 @default.
• W4385074337 creator A5089297467 @default.
• W4385074337 date "2023-11-01" @default.
• W4385074337 modified "2023-10-12" @default.
• W4385074337 title "EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy" @default.
• W4385074337 cites W1985928174 @default.
• W4385074337 cites W2752227448 @default.
• W4385074337 cites W2797309423 @default.
• W4385074337 cites W2952481429 @default.
• W4385074337 cites W3052274084 @default.
• W4385074337 doi "https://doi.org/10.1016/j.jaad.2023.06.057" @default.
• W4385074337 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37487833" @default.
• W4385074337 hasPublicationYear "2023" @default.
• W4385074337 type Work @default.
• W4385074337 citedByCount "0" @default.
• W4385074337 crossrefType "journal-article" @default.
• W4385074337 hasAuthorship W4385074337A5001548963 @default.
• W4385074337 hasAuthorship W4385074337A5004823373 @default.
• W4385074337 hasAuthorship W4385074337A5006114282 @default.
• W4385074337 hasAuthorship W4385074337A5006485099 @default.
• W4385074337 hasAuthorship W4385074337A5008492560 @default.
• W4385074337 hasAuthorship W4385074337A5015806707 @default.
• W4385074337 hasAuthorship W4385074337A5017218622 @default.
• W4385074337 hasAuthorship W4385074337A5019107852 @default.
• W4385074337 hasAuthorship W4385074337A5019984620 @default.
• W4385074337 hasAuthorship W4385074337A5022167252 @default.
• W4385074337 hasAuthorship W4385074337A5023198820 @default.
• W4385074337 hasAuthorship W4385074337A5027395430 @default.
• W4385074337 hasAuthorship W4385074337A5027968676 @default.
• W4385074337 hasAuthorship W4385074337A5031480514 @default.
• W4385074337 hasAuthorship W4385074337A5035779817 @default.
• W4385074337 hasAuthorship W4385074337A5055605020 @default.
• W4385074337 hasAuthorship W4385074337A5056320023 @default.
• W4385074337 hasAuthorship W4385074337A5072852205 @default.
• W4385074337 hasAuthorship W4385074337A5082278497 @default.
• W4385074337 hasAuthorship W4385074337A5083397493 @default.
• W4385074337 hasAuthorship W4385074337A5083713436 @default.
• W4385074337 hasAuthorship W4385074337A5087984672 @default.
• W4385074337 hasAuthorship W4385074337A5089297467 @default.
• W4385074337 hasConcept C121608353 @default.
• W4385074337 hasConcept C126322002 @default.
• W4385074337 hasConcept C143998085 @default.
• W4385074337 hasConcept C2777658100 @default.
• W4385074337 hasConcept C2777701055 @default.
• W4385074337 hasConcept C2777863537 @default.
• W4385074337 hasConcept C2777982462 @default.
• W4385074337 hasConcept C2780030458 @default.
• W4385074337 hasConcept C2780057760 @default.
• W4385074337 hasConcept C2781433595 @default.
• W4385074337 hasConcept C502942594 @default.
• W4385074337 hasConcept C71924100 @default.
• W4385074337 hasConceptScore W4385074337C121608353 @default.
• W4385074337 hasConceptScore W4385074337C126322002 @default.
• W4385074337 hasConceptScore W4385074337C143998085 @default.
• W4385074337 hasConceptScore W4385074337C2777658100 @default.
• W4385074337 hasConceptScore W4385074337C2777701055 @default.
• W4385074337 hasConceptScore W4385074337C2777863537 @default.
• W4385074337 hasConceptScore W4385074337C2777982462 @default.
• W4385074337 hasConceptScore W4385074337C2780030458 @default.
• W4385074337 hasConceptScore W4385074337C2780057760 @default.
• W4385074337 hasConceptScore W4385074337C2781433595 @default.
• W4385074337 hasConceptScore W4385074337C502942594 @default.
• W4385074337 hasConceptScore W4385074337C71924100 @default.
• W4385074337 hasIssue "5" @default.
• W4385074337 hasLocation W43850743371 @default.
• W4385074337 hasLocation W43850743372 @default.
• W4385074337 hasOpenAccess W4385074337 @default.
• W4385074337 hasPrimaryLocation W43850743371 @default.
• W4385074337 hasRelatedWork W2366936450 @default.
• W4385074337 hasRelatedWork W2899127460 @default.
• W4385074337 hasRelatedWork W2973740076 @default.
• W4385074337 hasRelatedWork W2976744492 @default.
• W4385074337 hasRelatedWork W3043703771 @default.
• W4385074337 hasRelatedWork W4236421112 @default.
• W4385074337 hasRelatedWork W4241093956 @default.

• next